Market Cap 8.07B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 14.75
Forward PE 12.26
Profit Margin 43.74%
Debt to Equity Ratio 4.54
Volume 2,657,000
Avg Vol 2,134,878
Day's Range N/A - N/A
Shares Out 116.97M
Stochastic %K 8%
Beta 1.16
Analysts Sell
Price Target $76.00

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Vikingsstrade
Vikingsstrade Oct. 4 at 5:53 PM
$KAPA $EPIX $HALO $STAK Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 3:27 AM
Enter: $HALO NOV 21 2025 $75 CALLS Buy in Price: $2.85 - $2.86 Take Profit: $5.72 Stop Bleeding: $2.52 ROI Potential: 100% Exit Within: 309 Minutes https://moneygroup.us/alerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 11:33 PM
$HALO: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $80 Exp on 11/21/2025 with Premium of $28K and showing BEARISH Sentiment
0 · Reply
highnihilism
highnihilism Oct. 3 at 6:56 PM
$NSC Norfolk Southern Trades: 165 | Total $: 420 K | 0.53 × 90-Day Avg $: 792.2 K | Call $: 319.6 K | Put $: 100.4 K | Single-Leg: 18% | Multi-Leg: 82% $SUI Sun Communities Trades: 22 | Total $: 314.5 K | 15.80 × 90-Day Avg $: 19.9 K | Call $: 314.5 K | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% $WES Western Midstream Partners Trades: 378 | Total $: 346.6 K | 1.58 × 90-Day Avg $: 219.5 K | Call $: 313.8 K | Put $: 32.7 K | Single-Leg: 94% | Multi-Leg: 1% | Contingent: 6% $HALO Halozyme Therapeutics Trades: 172 | Total $: 334.7 K | 1.12 × 90-Day Avg $: 298 K | Call $: 312.5 K | Put $: 22.2 K | Single-Leg: 91% | Multi-Leg: 7% | Contingent: 2%
0 · Reply
Sean29md
Sean29md Oct. 3 at 6:36 PM
$HALO Typically, the share price of an acquiring company goes down when the acquisition news is released. I think Halozyme went up on the announcement day at least partially because of the favorable CMS ruling. But now the market is digesting the acquisition news. If you believe this is a good acquisition, then this would be a great opportunity to load up more. The stock will be recover and then some. If you don't like the acquisition, the stock has already been punished even more than the cost of the acquisition so it's hard to imagine it would go down much more. It is possible that one of the funds is unloading. Either way fundamentals will ultimately rule. We have a 2025 PE in the low teens, a fat profit margin and a EPS CAGR of &30+
1 · Reply
Following_the_trend
Following_the_trend Oct. 3 at 3:27 PM
$HALO Rut Roe, Too close to my stop
0 · Reply
buddyopalosam
buddyopalosam Oct. 3 at 2:59 PM
$HALO mid 50's and you buy it again.
0 · Reply
Sean29md
Sean29md Oct. 2 at 4:42 PM
$HALO Halozyme is a great company, has done very well for investors and has a bright future. Phat profit margins, low PE and EPS CAGR of +30%. It's growth and value combined into one comapny. It is and has been a great stock for investors not just because of its multiyear upward trends but equally importantly, it gives investors nice discounts to load up more from time to time. Enjoy the bargain shopping at +%15! If you don't love buying absolute quality at a discount, investing is not for you.
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 3:21 PM
$HALO gap fill at 61 still in play.
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 2 at 12:56 PM
$HALO With $1.179B in trailing revenue and royalties surging 65% YoY, Halozyme is turning its ENHANZE platform into a biotech money engine. https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/
0 · Reply
Latest News on HALO
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 3 days ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript


Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 5 weeks ago

Identify Superstar Stocks Like Halozyme with Money Flows


Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 5 weeks ago

Halozyme to Participate at Upcoming Investor Conferences


Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 3 months ago

Halozyme Therapeutics Added to Russell 1000® Index


Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 5 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat


Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 5 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings


Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 7 months ago

Halozyme Joins the $1 Billion Club


Halozyme: Recent Approvals Alter My Appetite

Dec 31, 2024, 2:41 AM EST - 9 months ago

Halozyme: Recent Approvals Alter My Appetite


Halozyme to Present at Upcoming Investor Conferences

Nov 27, 2024, 8:30 AM EST - 11 months ago

Halozyme to Present at Upcoming Investor Conferences


Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 11 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO


Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 11 months ago

Halozyme CEO: Evotec Is Poised for Growth

EVO


Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 5, 2024, 12:24 PM EST - 11 months ago

Halozyme: Looking For More Growth Following Record Q3 Earnings


Vikingsstrade
Vikingsstrade Oct. 4 at 5:53 PM
$KAPA $EPIX $HALO $STAK Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 3:27 AM
Enter: $HALO NOV 21 2025 $75 CALLS Buy in Price: $2.85 - $2.86 Take Profit: $5.72 Stop Bleeding: $2.52 ROI Potential: 100% Exit Within: 309 Minutes https://moneygroup.us/alerts
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 11:33 PM
$HALO: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $80 Exp on 11/21/2025 with Premium of $28K and showing BEARISH Sentiment
0 · Reply
highnihilism
highnihilism Oct. 3 at 6:56 PM
$NSC Norfolk Southern Trades: 165 | Total $: 420 K | 0.53 × 90-Day Avg $: 792.2 K | Call $: 319.6 K | Put $: 100.4 K | Single-Leg: 18% | Multi-Leg: 82% $SUI Sun Communities Trades: 22 | Total $: 314.5 K | 15.80 × 90-Day Avg $: 19.9 K | Call $: 314.5 K | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% $WES Western Midstream Partners Trades: 378 | Total $: 346.6 K | 1.58 × 90-Day Avg $: 219.5 K | Call $: 313.8 K | Put $: 32.7 K | Single-Leg: 94% | Multi-Leg: 1% | Contingent: 6% $HALO Halozyme Therapeutics Trades: 172 | Total $: 334.7 K | 1.12 × 90-Day Avg $: 298 K | Call $: 312.5 K | Put $: 22.2 K | Single-Leg: 91% | Multi-Leg: 7% | Contingent: 2%
0 · Reply
Sean29md
Sean29md Oct. 3 at 6:36 PM
$HALO Typically, the share price of an acquiring company goes down when the acquisition news is released. I think Halozyme went up on the announcement day at least partially because of the favorable CMS ruling. But now the market is digesting the acquisition news. If you believe this is a good acquisition, then this would be a great opportunity to load up more. The stock will be recover and then some. If you don't like the acquisition, the stock has already been punished even more than the cost of the acquisition so it's hard to imagine it would go down much more. It is possible that one of the funds is unloading. Either way fundamentals will ultimately rule. We have a 2025 PE in the low teens, a fat profit margin and a EPS CAGR of &30+
1 · Reply
Following_the_trend
Following_the_trend Oct. 3 at 3:27 PM
$HALO Rut Roe, Too close to my stop
0 · Reply
buddyopalosam
buddyopalosam Oct. 3 at 2:59 PM
$HALO mid 50's and you buy it again.
0 · Reply
Sean29md
Sean29md Oct. 2 at 4:42 PM
$HALO Halozyme is a great company, has done very well for investors and has a bright future. Phat profit margins, low PE and EPS CAGR of +30%. It's growth and value combined into one comapny. It is and has been a great stock for investors not just because of its multiyear upward trends but equally importantly, it gives investors nice discounts to load up more from time to time. Enjoy the bargain shopping at +%15! If you don't love buying absolute quality at a discount, investing is not for you.
0 · Reply
Okadarlan
Okadarlan Oct. 2 at 3:21 PM
$HALO gap fill at 61 still in play.
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 2 at 12:56 PM
$HALO With $1.179B in trailing revenue and royalties surging 65% YoY, Halozyme is turning its ENHANZE platform into a biotech money engine. https://biotechhealthx.com/biotech-news/halozyme-halo-reports-1-179b-revenue-and-65-royalty-growth/
0 · Reply
Bulldog344
Bulldog344 Oct. 2 at 10:36 AM
$HALO thinking this trades lower while MRK trial gets news and the buyout costs hit earnings but long term is probably good
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 10:34 AM
HC Wainwright & Co. has adjusted their stance on Halozyme Therapeutics ( $HALO ), setting the rating to Buy with a target price of 85 → 90.
0 · Reply
Bulldog344
Bulldog344 Oct. 2 at 10:33 AM
0 · Reply
Halo202
Halo202 Oct. 2 at 1:12 AM
$HALO Called it
1 · Reply
Sean29md
Sean29md Oct. 1 at 3:25 PM
0 · Reply
Biotech102
Biotech102 Oct. 1 at 3:15 PM
$HALO multiple positive developments today!! This should be $100+ the valuation is way too cheap
0 · Reply
Sean29md
Sean29md Oct. 1 at 2:53 PM
$HALO from Citizens JMP analyst Jason Butler: "Clarity on CMS combination drug policy is a clear win for ENHANZE, and we believe future policies will continue to recognize the clinically meaningful benefits the technology drives. YESTERDAY afternoon, CMS published its final guidance for 2028 IRA Medicare drug price negotiations. Recall that the draft guidance announced in May 2025 raised concerns and pressured HALO shares as it was interpreted by some as negative for combination products leveraging the ENHANZE technology (see our note here). The final guidance makes no changes to the combination drug policy, which we expect will be viewed as a clear win for HALO shares this morning. Most importantly in our view, we remain confident that ENHANZE drives clinically meaningful benefit to the combination drugs it enables, and therefore, even with potential for CMS to revisit this topic for the 2029 policy, we do not expect any changes that would negatively impact ENHANZE royalties."
0 · Reply
Okadarlan
Okadarlan Oct. 1 at 2:51 PM
$HALO 40 ? glitch spot.
0 · Reply
Sean29md
Sean29md Oct. 1 at 1:27 PM
$HALO Also, CMS final guidance last night was favorable to Halozyme. Under the final IPAY 2028 guidance, a combination therapeutic + delivery agent (if the delivery agent is treated as an active moiety in FDA labeling etc.) will likely continue to be viewed as a fixed combination, not aggregated with a single-ingredient drug in the way you had hoped. There is no special carve-out in the final guidance that says: “we will treat delivery agents differently / ignore them for aggregation or timing.” However, CMS has left the door open to future change: they explicitly plan to revisit the fixed combination policy in rulemaking for the 2029 cycle. CMS still retains flexibility to issue program instruction or further clarifications during implementation of this guidance.
0 · Reply
notreload_ai
notreload_ai Oct. 1 at 12:50 PM
$HALO is buying Elektrofi ($900M) for Hypercon tech. This innovation concentrates powerful biologic drugs for small, easy shots. This means patients can use auto-injectors at home, boosting convenience and treatment access. https://notreload.xyz/halozyme-900m-elektrofi-acquisition-hypercon-technology/
0 · Reply
JR603
JR603 Sep. 30 at 6:26 PM
$HALO The Core of the Dispute Halozyme's Claim: Halozyme alleges that Merck's SC Keytruda uses its patented MDASE™ technology—a modified hyaluronidase enzyme that allows drugs to be delivered subcutaneously instead of intravenously—without a license. Halozyme seeks damages and an injunction to stop the infringement. Merck's Counterclaim: Merck asserts that the patents are invalid, claiming they do not solve a technical problem and that their key features are arbitrary and ill-defined. Merck's SC Keytruda uses a different modified enzyme, "berahyaluronidase alfa," which it argues is not infringing.
0 · Reply
JR603
JR603 Sep. 30 at 6:24 PM
$HALO On September 30, 2025, Merck & Co. filed a reply and defense in a London court against Halozyme Therapeutics' patent infringement claims over Merck's subcutaneous (SC) Keytruda, arguing Halozyme's patents for a subcutaneous drug delivery system do not solve a technical problem and are therefore invalid. This filing follows Merck's August lawsuit challenging the patents and Halozyme's early September accusation of infringement, as Merck plans to launch its own SC Keytruda in October 2025.
0 · Reply